pH and ROS Dual‐Sensitive Nanocarriers for the Targeted Co‐Delivery and On‐Demand Sequential Release of Tofacitinib and Glucosamine for Synergistic Rheumatoid Arthritis Treatment

Author:

Chen Guo12,Deng Shaohui3,Liu Shubo1,Zhao Yuexin1,Xiao Yuanqiang4,Zeng Xiangming3,Xu Yafei2,Cheng Du3ORCID,Chen Bin1

Affiliation:

1. Division of Orthopaedics and Traumatology Department of Orthopaedics Nanfang Hospital Southern Medical University Guangzhou 510515 P. R. China

2. Department of Orthopaedics and Traumatology The Seventh Affiliated Hospital Southern Medical University Foshan 528244 P. R. China

3. PCFM Lab of Ministry of Education School of Material Science and Engineering Sun Yat‐Sen University Guangzhou 510275 P. R. China

4. Department of Radiology The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510630 P. R. China

Abstract

AbstractRheumatoid arthritis (RA) progression involves multiple cell types, and sequential drug action on target cells is necessary for RA treatment. Nanocarriers are widely used for RA treatment; however, the targeted delivery and on‐demand release of multiple drugs remains challenging. Therefore, in this study, a dual‐sensitive polymer is developed using chondroitin sulfate (CS) for the co‐delivery of the cartilage repair agent, glucosamine (GlcN), and anti‐inflammatory drug, tofacitinib (Tof). In the joint cavity, acidic pH facilitates the cleavage of GlcN from CS polymer to repair the cartilage damage. Subsequently, macrophage uptake via CS–CD44 binding and intracellular reactive oxygen species (ROS) mediate conversion of (methylsulfanyl)propylamine to a hydrophilic segment jointly triggered rapid Tof/GlcN release via micelle disassembly. The combined effects of Tof, GlcN, and ROS depletion promote the M1‐to‐M2 polarization shift to attenuate inflammation. The synergistic effects of these agents against RA are confirmed in vitro and in vivo. Overall, the dual pH/ROS‐sensitive CS nanoplatform simultaneously delivers GlcN and Tof, providing a multifunctional approach for RA treatment with synergistic drug effects.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Biomaterials,Biotechnology,General Materials Science,General Chemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3